Table Info

Table 1.

FDA-approved CAR-T cell therapies

Name	Target antigen	Disease	Year of approval
Tisagenlecleucel (Kymriah)	CD19	B-ALL, NHL	2017
Axicabtagene ciloleucel (Yescarta)	CD19	NHL, follicular lymphoma	2017
Brexucabtagene autoleucel (Tecartus)	CD19	MCL, B-ALL	2021
Lisocabtagene maraleucel (Breyanzi)	CD19	NHL	2021
Idecabtagene vicleucel (Abecma)	BCMA	Multiple myeloma	2021
Ciltacabtagene autoleucel (Carvykti)	BCMA	Multiple myeloma	2022

B-ALL: B cell acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; MCL: mantle cell lymphoma

Declarations

Author contributions

CS: Writing—original draft, Writing—review & editing. JE, ITO, MA, SRK, TT: Writing—review & editing. SRB: Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was supported by the German Federal Ministry of Education [Clusters4Future SaxoCell, 03ZU1111DA]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Lichti CF, Wan XX. Using mass spectrometry to identify neoantigens in autoimmune diseases: the type 1 diabetes example. Semin Immunol. 2023;66:101730. [DOI] [PubMed] [PMC]

Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Front Immunol. 2023;14:1126421. [DOI] [PubMed] [PMC]

Serra P, Santamaria P. Antigen-specific therapeutic approaches for autoimmunity. Nat Biotechnol. 2019;37:238–51. [DOI] [PubMed]

Alzabin S, Venables PJ. Etiology of autoimmune disease: past, present and future. Expert Rev Clin Immunol. 2012;8:111–3. [DOI] [PubMed]

Waisman A, Johann L. Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. J Mol Med (Berl). 2018;96:1279–92. [DOI] [PubMed]

Firdessa FR, Bechi Genzano CB, Mallone R, Creusot RJ. Epitope-based precision immunotherapy of type 1 diabetes. Hum Vaccin Immunother. 2023;19:2154098. [DOI] [PubMed] [PMC]

Abela AG, Fava S. Why is the incidence of type 1 diabetes increasing? Curr Diabetes Rev. 2021;17:e030521193110. [DOI] [PubMed]

Richardson SJ, Pugliese A. 100 years of insulin: pancreas pathology in type 1 diabetes: an evolving story. J Endocrinol. 2021;252:R41–57. [DOI] [PubMed]

Steenblock C, Hassanein M, Khan EG, Yaman M, Kamel M, Barbir M, et al. Diabetes and COVID-19: short- and long-term consequences. Horm Metab Res. 2022;54:503–9. [DOI] [PubMed] [PMC]

10.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the american diabetes association. Diabetes Care. 2015;38:1964–74. [DOI] [PubMed] [PMC]

11.

Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:364–89. [DOI] [PubMed] [PMC]

12.

Bornstein SR, Ludwig B, Steenblock C. Progress in islet transplantation is more important than ever. Nat Rev Endocrinol. 2022;18:389–90. [DOI] [PubMed] [PMC]

13.

Ludwig S, Distler M, Schubert U, Schmid J, Thies H, Welsch T, et al. Quality of life and metabolic outcomes after total pancreatectomy and simultaneous islet autotransplantation. Commun Med. 2022;2:24. [DOI] [PubMed] [PMC]

14.

Brusko TM, Russ HA, Stabler CL. Strategies for durable β cell replacement in type 1 diabetes. Science. 2021;373:516–22. [DOI] [PubMed] [PMC]

15.

Verhoeff K, Marfil-Garza BA, Shapiro AMJ. Update on islet cell transplantation. Curr Opin Organ Transplant. 2021;26:397–404. [DOI] [PubMed]

16.

Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple RK, Gewert C, Brown RJ, et al. Combined immunosuppressive therapy induces remission in patients with severe type B insulin resistance: a prospective cohort study. Diabetes Care. 2018;41:2353–60. [DOI] [PubMed] [PMC]

17.

Deltour JB, d’Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, et al. Efficacy of rituximab in patients with Graves’ orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258:2013–21. [DOI] [PubMed]

18.

Napier C, Gan EH, Mitchell AL, Gilligan LC, Rees DA, Moran C, et al. Residual adrenal function in autoimmune addison’s disease—effect of dual therapy with rituximab and depot tetracosactide. J Clin Endocrinol Metab. 2020;105:e1250–9. [DOI] [PubMed] [PMC]

19.

Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21:149–56. [DOI] [PubMed]

20.

Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al.; PEMPHIX Study Group. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384:2295–305. [DOI] [PubMed]

21.

Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401:815–8. [DOI] [PubMed]

22.

Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124–32. [DOI] [PubMed]

23.

Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385:567–9. [DOI] [PubMed]

24.

Wang C, Liu J, Li W. ‘Off the shelf’ immunotherapies: generation and application of pluripotent stem cell-derived immune cells. Cell Prolif. 2023;56:e13425. [DOI] [PubMed] [PMC]

25.

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520–31. [DOI] [PubMed] [PMC]

26.

Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy. Stem Cells. 2018;36:134–45. [DOI] [PubMed] [PMC]

27.

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7. [DOI] [PubMed]

28.

Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330–8. [DOI] [PubMed] [PMC]

29.

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016;20:1287–94. [DOI] [PubMed] [PMC]

30.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265–73. [PubMed]

31.

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545–53. [DOI] [PubMed] [PMC]

32.

Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563–70. [DOI] [PubMed]

33.

Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother. 2018;67:25–38. [DOI] [PubMed]

34.

Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10:535–44. [DOI] [PubMed]

35.

Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25:451–7. [DOI] [PubMed]

36.

Wang S, Chen K, Jiang Y, Zhao G, Wang C, Fang H, et al. Breaking boundaries: current progress of anticancer NK cell-based drug development. Drug Discov Today. 2023;28:103436. [DOI] [PubMed]

37.

Chen J, Liao S, Zhou H, Yang L, Guo F, Chen S, et al. Humanized mouse models of systemic lupus erythematosus: opportunities and challenges. Front Immunol. 2021;12:816956. [DOI] [PubMed] [PMC]

38.

Miller JM, Meki MH, Elnakib A, Ou Q, Abouleisa RRE, Tang X-L, et al. Biomimetic cardiac tissue culture model (CTCM) to emulate cardiac physiology and pathophysiology ex vivo. Commun Biol. 2022;5:934. [DOI] [PubMed] [PMC]